US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23-07-2020
Gilead agrees 127-country remdesivir licence with generic makers
14-05-2020
Taljat David / Shutterstock.com
China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Junshi Biosciences, Lonza, antibody, COVID-19, vaccine, gene expression, GS Xceed, remdesivir, antiviral, Gilead, licence
